ANIPANI Pharmaceuticals, Inc.
$73.92-24% 1Y
$73.92
$70.1652 weeks$95.93
ANIP in its own filings
ANIP's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
515
Events found in the filings · across 1,776 filings · the record starts in 2000
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 24, 2026
Most recent filing · Form 8-K
- Record starts
- May 1, 2000
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 6, 2026
- Change in certifying accountant2 occurrences
- 2026-04-07
- Delisting notice / listing-rule failure3 occurrences
- 2020-05-14
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2007-11-02
- SEC comment-letter activity50 occurrences
- 2023-01-30
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 24, 2026On August 19, 2026, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company’s 2027 annual meeting of stockholders.Director or officer change · Form 8-K
- Aug 7, 2026ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results.Earnings release · press release
- May 21, 2026ANI Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 21, 2026. At the Annual Meeting, the stockholders of the Company approved the Company’s Amended and Restated 2022 Stock Incentive Plan (the “Amended 2022 Stock Plan”)Director or officer change · Form 8-K
- May 8, 2026ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance.Earnings release · press release
- Apr 7, 2026Dismissal of Independent Registered Public Accounting Firm On April 1, 2026, ANI Pharmaceuticals, Inc. (the “Company”) notified EisnerAmper LLP (“EisnerAmper”) that EisnerAmper would be dismissed as the Company’s independent registered public accounting firm.Auditor change · Form 8-K
- Dec 1, 2025On November 24, 2025, Patrick D. Walsh notified the Company that he will not seek re-election as a director at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), but will continue to serve as a director until the Annual Meeting.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #9 of 41 by RyuScore